[go: up one dir, main page]

PE20050066A1 - Formulaciones farmaceuticas liquidas de palonosetron - Google Patents

Formulaciones farmaceuticas liquidas de palonosetron

Info

Publication number
PE20050066A1
PE20050066A1 PE2004000115A PE2004000115A PE20050066A1 PE 20050066 A1 PE20050066 A1 PE 20050066A1 PE 2004000115 A PE2004000115 A PE 2004000115A PE 2004000115 A PE2004000115 A PE 2004000115A PE 20050066 A1 PE20050066 A1 PE 20050066A1
Authority
PE
Peru
Prior art keywords
approximately
palonosetron
formulations
pharmaceutical formulations
liquid pharmaceutical
Prior art date
Application number
PE2004000115A
Other languages
English (en)
Inventor
Giorgio Calderari
Daniele Bonadeo
Enrico Braglia
Riccardo Braglia
Roberta Cannella
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32825409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050066(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of PE20050066A1 publication Critical patent/PE20050066A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B3/04—Methods of, or means for, filling the material into the containers or receptacles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B55/00—Preserving, protecting or purifying packages or package contents in association with packaging
    • B65B55/02—Sterilising, e.g. of complete packages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mechanical Engineering (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A FORMULACIONES LIQUIDAS DEL COMPUESTO (3aS)-2,3,3a,4,5,6-HEXAHIDRO-2-[(S)-1-AZABICICLO[2,2,2]OCT-3-IL]2,3,3a,4,5,6-HEXAHIDRO-1-OXO-1H-BENZO[de]ISOQUINOLINA, CONOCIDO COMO PALONOSETRON, CARACTERIZADAS POR SER ESTABLES ANTE EL ALMACENAMIENTO DURANTE PERIODOS PROLONGADOS, Y PERMITEN EL USO DE CONCENTRACIONES INFERIORES A LAS QUE SE PODRIA ESPERAR NORMALMENTE, CARACTERIZADO PORQUE COMPRENDE ENTRE APROXIMADAMENTE 0,01 mg/ml Y 5 mg/ml DE CLORHIDRATO DE PALONOSETRON Y UN VEHICULO ACEPTABLE A UN Ph ENTRE APROXIMADAMENTE 4,0 Y 6,0 Y ENTRE APROXIMADAMENTE 10 Y 100 MILIMOLES DE SOLUCION AMORTIGUADORA DE pH AL CITRATO, Y ENTRE APROXIMADAMENTE 0,005 Y 1,0 mg/ml DE EDTA. SI SE AGREGA MANITOL Y UN AGENTE QUELANTE SE PUEDE AUMENTAR LA ESTABILIDAD DE LAS FORMULACIONES. SON UTILES PARA REDUCIR LA EMESIS INDUCIDA POR QUIMIOTERAPIA Y RADIOTERAPIA Y SUS FORMULACIONES SE EMPLEAN EN LA PREPARACION DE MEDICAMENTOS LIQUIDOS INTRAVENOSOS Y ORALES
PE2004000115A 2003-01-30 2004-01-30 Formulaciones farmaceuticas liquidas de palonosetron PE20050066A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44435103P 2003-01-30 2003-01-30

Publications (1)

Publication Number Publication Date
PE20050066A1 true PE20050066A1 (es) 2005-04-20

Family

ID=32825409

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000115A PE20050066A1 (es) 2003-01-30 2004-01-30 Formulaciones farmaceuticas liquidas de palonosetron

Country Status (40)

Country Link
US (9) US7947724B2 (es)
EP (2) EP2008659A1 (es)
JP (2) JP5461763B2 (es)
KR (1) KR101113084B1 (es)
CN (2) CN1758911A (es)
AP (1) AP2110A (es)
AR (1) AR042977A1 (es)
AT (1) ATE410167T1 (es)
AU (1) AU2004208505C1 (es)
BR (1) BRPI0407121B8 (es)
CA (5) CA2573241A1 (es)
CR (1) CR7921A (es)
CY (1) CY1108660T1 (es)
DE (1) DE602004016967D1 (es)
DK (1) DK1601359T3 (es)
EA (1) EA014066B1 (es)
EC (1) ECSP055938A (es)
ES (1) ES2315635T3 (es)
GE (1) GEP20084445B (es)
HR (1) HRP20050676B1 (es)
IL (1) IL169859A (es)
IS (1) IS7984A (es)
JO (1) JO2735B1 (es)
MA (1) MA27710A1 (es)
MX (1) MXPA05008028A (es)
MY (1) MY144036A (es)
NO (1) NO329500B1 (es)
NZ (1) NZ541533A (es)
PA (1) PA8594801A1 (es)
PE (1) PE20050066A1 (es)
PL (1) PL378398A1 (es)
PT (1) PT1601359E (es)
RS (1) RS20050578A (es)
SI (1) SI1601359T1 (es)
TN (1) TNSN05180A1 (es)
TW (1) TWI342212B (es)
UA (1) UA90449C2 (es)
UY (1) UY28175A1 (es)
WO (1) WO2004067005A1 (es)
ZA (1) ZA200506917B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5690461B2 (ja) * 2002-11-15 2015-03-25 ヘルシン ヘルスケア ソシエテ アノニム 化学療法誘導嘔吐を治療するためのパロノセトロン
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
TWI355936B (en) * 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
CN100336508C (zh) * 2005-02-23 2007-09-12 重庆医药工业研究院有限责任公司 一种稳定的帕洛诺司琼注射液
CN100455286C (zh) * 2006-11-21 2009-01-28 深圳海创医药科技发展有限公司 帕洛诺司琼注射液及其制备方法
US9061076B2 (en) 2007-05-25 2015-06-23 North Carolina State University Viral nanoparticle cell-targeted delivery platform
US20100048607A1 (en) * 2008-08-25 2010-02-25 Chandrashekhar Kocherlakota Formulations comprising palonosetron
EP2364138A2 (en) 2008-12-08 2011-09-14 Teva Pharmaceutical Industries Ltd. Palonosetron formulation
US20130213393A1 (en) 2009-12-22 2013-08-22 Evoke Pharma, Inc. Nasal formulations of metoclopramide
WO2011058427A1 (en) 2009-11-13 2011-05-19 Helsinn Healthcare S.A. Palonosetron metabolites
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
ES2623503T3 (es) 2009-11-18 2017-07-11 Helsinn Healthcare Sa Composiciones para tratar náuseas y vómitos mediados centralmente
KR101368587B1 (ko) * 2010-12-27 2014-03-05 주식회사 삼양바이오팜 오심 또는 구토 방지용 조성물
JP2014530249A (ja) 2011-10-18 2014-11-17 ヘルシン ヘルスケア ソシエテ アノニム ネツピタントおよびパロノセトロンの治療学的組合せ
WO2015099381A1 (ko) 2013-12-23 2015-07-02 주식회사 삼양바이오팜 팔로노세트론을 함유하는 약학 조성물
CN104784107A (zh) * 2014-01-17 2015-07-22 南京瑞尔医药有限公司 一种盐酸托烷司琼口服液的制备方法
KR20160128573A (ko) * 2015-04-29 2016-11-08 주식회사 삼양바이오팜 약제학적 패키지
UA122285C2 (uk) * 2016-06-06 2020-10-12 Хелсінн Хелскеа Са Фізіологічно збалансовані склади для ін'єкцій, які включають фоснетупітант
JP6768404B2 (ja) * 2016-08-12 2020-10-14 武田テバファーマ株式会社 パロノセトロン又はその薬学的に許容される塩を含む医薬組成物
JP6705348B2 (ja) * 2016-09-23 2020-06-03 ニプロ株式会社 液体製剤、及び、パロノセトロンの安定性を向上する方法
JP6642377B2 (ja) * 2016-10-25 2020-02-05 ニプロ株式会社 液体製剤、及び、パロノセトロンの安定性を向上する方法
KR101802183B1 (ko) * 2016-11-16 2017-11-28 주식회사 유영제약 팔로노세트론을 활성성분으로 함유하는 약제학적 조성물
US11517545B2 (en) 2016-12-15 2022-12-06 Evoke Pharma, Inc. Treatment of moderate and severe gastroparesis
WO2019038656A1 (en) 2017-08-21 2019-02-28 Leiutis Pharmaceuticals Pvt, Ltd NEW TRIPLE COMBINATION FORMULATIONS FOR ANTIEMETIC THERAPY
HRP20230471T1 (hr) * 2018-01-12 2023-07-21 Orion Corporation Palonsetron kapi za oči za liječenje ili prevenciju mučnine i povraćanja
JP7090845B2 (ja) * 2018-08-03 2022-06-27 高田製薬株式会社 パロノセトロン含有液体組成物
JP7438802B2 (ja) * 2020-03-23 2024-02-27 シオノギファーマ株式会社 パロノセトロン含有組成物
TW202428273A (zh) * 2023-01-03 2024-07-16 瑞士商赫爾辛保健公司 奈妥吡坦(netupitant)及帕洛諾司瓊(palonosetron)的液態口服調配物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS599539B2 (ja) * 1979-11-13 1984-03-03 日本化薬株式会社 ニトログリセリン水溶液及びその製造法
US4695578A (en) 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
EP0200444B1 (en) 1985-04-27 1992-11-11 Beecham Group Plc Azabicyclononyl-indazole-carboxamide having 5-ht antagonist activity
US4937247A (en) 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
GB8516083D0 (en) 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
US5240954A (en) 1985-06-25 1993-08-31 Glaxo Group Limited Medicaments
US5578628A (en) 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
US4906755A (en) 1986-11-03 1990-03-06 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds
US5360800A (en) 1987-09-03 1994-11-01 Glaxo Group Limited Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives
US5011846A (en) 1988-02-23 1991-04-30 Merrell Dow Pharmaceuticals Inc. Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
GB8914804D0 (en) 1989-06-28 1989-08-16 Glaxo Group Ltd Process
US5344658A (en) 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron
DK0430190T3 (da) * 1989-11-28 1995-08-21 Syntex Inc Hidtil ukendte tricykliske forbindelser
JP3222891B2 (ja) 1991-05-03 2001-10-29 ジー．ディー．サール アンド カンパニー 置換ベンゾオキサゼピン化合物、医薬品組成物およびその使用方法
US5272137A (en) 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
GB9305593D0 (en) * 1993-03-18 1993-05-05 Smithkline Beecham Plc Pharmaceuticals
US5567818A (en) * 1994-07-08 1996-10-22 Syntex (U.S.A.) Inc. Processes for preparing 2-(1-azabicyclo[2.2.2]oct-3-yl)-1H-benz[de] isoquinolin-1-one derivatives and intermediates useful therein
GB9423588D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB9423511D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
JP3845902B2 (ja) * 1996-07-09 2006-11-15 ソニー株式会社 磁気記録再生装置
ATA156496A (de) 1996-09-03 1997-10-15 Nycomed Austria Gmbh Pharmazeutische zusammensetzung
GB9625589D0 (en) * 1996-12-10 1997-01-29 Boots Co Plc Therapeutic agents
US20030095926A1 (en) 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
GB9721139D0 (en) 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
US6294548B1 (en) 1998-05-04 2001-09-25 Hoffmann-La Roche Inc. Multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
US6132758A (en) 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
DE19833119A1 (de) 1998-07-23 2000-01-27 Roche Diagnostics Gmbh Spritzfertige Injektionslösungen enthaltend Carvedilol
DE69904498T2 (de) * 1998-10-27 2003-04-24 Alcon Laboratories, Inc. Konservierungsmittel für lokale pharmazeutische zubereitungen enthaltend eine fettsäure/aminosäure enthaltende seife
BR0116429A (pt) 2000-12-20 2006-05-09 Bristol Myers Squibb Co piridoindóis substituìdos como agonistas e antagonistas da serotonina
JP4302990B2 (ja) 2001-05-11 2009-07-29 田辺三菱製薬株式会社 安定かつ高濃度であるピラゾロン誘導体を含む注射剤
AU2003237657A1 (en) 2002-05-24 2003-12-12 Epidauros Biotechnologie Ag Means and methods for improved treatment using "setrones"
JP5690461B2 (ja) * 2002-11-15 2015-03-25 ヘルシン ヘルスケア ソシエテ アノニム 化学療法誘導嘔吐を治療するためのパロノセトロン
US7109339B2 (en) 2002-12-19 2006-09-19 Bristol-Myers Squibb Company Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
ES2285407T3 (es) 2003-01-13 2007-11-16 Dynogen Pharmaceuticals Inc. Metodo para el tratamiento de nauseas, vomitos, arcadas o cualquiera de sus combinaciones.
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
TWI355936B (en) * 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride

Also Published As

Publication number Publication date
AP2110A (en) 2010-03-01
US20060167071A1 (en) 2006-07-27
AU2004208505B2 (en) 2009-09-03
US9308266B2 (en) 2016-04-12
ES2315635T3 (es) 2009-04-01
MY144036A (en) 2011-07-29
US7947725B2 (en) 2011-05-24
EP1601359A1 (en) 2005-12-07
US20160000773A1 (en) 2016-01-07
AP2005003382A0 (en) 2005-09-30
AU2004208505A1 (en) 2004-08-12
US7960424B2 (en) 2011-06-14
CA2514224A1 (en) 2004-08-12
CA2573241A1 (en) 2004-08-12
UY28175A1 (es) 2004-09-30
TW200418517A (en) 2004-10-01
US20140097114A1 (en) 2014-04-10
HRP20050676B1 (hr) 2013-02-28
NO329500B1 (no) 2010-11-01
AR042977A1 (es) 2005-07-13
BRPI0407121B1 (pt) 2018-07-17
DE602004016967D1 (de) 2008-11-20
KR101113084B1 (ko) 2012-02-15
BRPI0407121B8 (pt) 2021-06-29
UA90449C2 (ru) 2010-05-11
ATE410167T1 (de) 2008-10-15
BRPI0407121A (pt) 2006-01-10
CA2573228A1 (en) 2004-08-12
US20140039000A1 (en) 2014-02-06
EA014066B1 (ru) 2010-08-30
PA8594801A1 (es) 2004-09-16
HK1076401A1 (en) 2006-01-20
IS7984A (is) 2005-08-15
NZ541533A (en) 2008-12-24
JO2735B1 (en) 2013-09-15
JP5551658B2 (ja) 2014-07-16
AU2004208505C1 (en) 2015-10-01
US8518981B2 (en) 2013-08-27
AU2004208505A2 (en) 2004-08-12
PL378398A1 (pl) 2006-04-03
PT1601359E (pt) 2008-11-03
SI1601359T1 (sl) 2009-04-30
CY1108660T1 (el) 2014-04-09
US20060069114A1 (en) 2006-03-30
US20060167073A1 (en) 2006-07-27
EP2008659A1 (en) 2008-12-31
IL169859A (en) 2014-11-30
DK1601359T3 (da) 2009-01-05
MA27710A1 (fr) 2006-01-02
EA200501203A1 (ru) 2006-06-30
MXPA05008028A (es) 2006-01-27
CA2573363A1 (en) 2004-08-12
NO20053987L (no) 2005-08-26
CN1758911A (zh) 2006-04-12
US9457020B2 (en) 2016-10-04
CR7921A (es) 2006-02-07
JP2006516583A (ja) 2006-07-06
WO2004067005A1 (en) 2004-08-12
US8598218B2 (en) 2013-12-03
RS20050578A (sr) 2007-09-21
US20110192493A1 (en) 2011-08-11
JP2011236242A (ja) 2011-11-24
CA2514224C (en) 2009-11-03
CA2573194A1 (en) 2004-08-12
ZA200506917B (en) 2006-08-30
US20130267553A1 (en) 2013-10-10
HRP20050676A2 (en) 2005-10-31
TWI342212B (en) 2011-05-21
JP5461763B2 (ja) 2014-04-02
TNSN05180A1 (en) 2007-06-11
EP1601359B1 (en) 2008-10-08
US20160317440A1 (en) 2016-11-03
GEP20084445B (en) 2008-08-10
CN102813621A (zh) 2012-12-12
ECSP055938A (es) 2006-03-01
KR20050104363A (ko) 2005-11-02
US7947724B2 (en) 2011-05-24

Similar Documents

Publication Publication Date Title
PE20050066A1 (es) Formulaciones farmaceuticas liquidas de palonosetron
BR9912694A (pt) Composto para preparar medicamento de administração pulmonar
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
DE69812343D1 (de) Feste pharmazeutische formulierungen enthaltend eine physische mischung aus sulphoalkylethercyclodextrin und einem therapeutischen wirkstoff
PA8509001A1 (es) Forma de dosificacion de farmacos accionada por un hidrogel
ATE429210T1 (de) Orale flüssige zusammensetzungen
ES2163444T3 (es) Composiciones y metodos para la administracion oral de farmacos.
ES2110377T1 (es) Formulacion galenica de fenofibrato y aplicacion de la misma.
ATE391708T1 (de) Verbindungen und gemische zur verabreichung eines aktiven agens
BRPI0414000B8 (pt) composição farmacêutica sólida oral de liberação prolongada contendo tacrolimus na forma de uma dispersão sólida, forma de dosagem, e, uso da composição farmacêutica
ES2160577T3 (es) Nuevos esteres de aminoalcoholes biciclicos y triciclicos, su preparacion y su utilizacion en medicamentos.
EP1708686A4 (en) GENERAL LINEAR SHELL FORM OF FENTANYL FOR ORAL USE AND METHOD OF ADMINISTRATION
ES2160693T3 (es) Formulacion estable de 10-hidroxi-7-etil-camptotecina en la forma lactona.
EA200100298A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ С РЕГУЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ, СОДЕРЖАЩИЕ ИНГИБИТОР cGMP-ФОСФОДИЭСТЕРАЗЫ-5
CA3123813C (en) IMPROVED GLIBENCLAMIDE FORMULATIONS AND RELATED FREEZE-DRYING METHODS, AND FREEZE-DRY SATE PRODUCED THUS
ATE202931T1 (de) Taxanderivate enthaltende arzneizubereitungen
SV2002000969A (es) Composicion parenteral reconstituible
ATE240344T1 (de) Nor-pregnane zur induzierung hypothalamischer effekte
AR029373A1 (es) Metodo para el tratamiento de migranas, utilizando compuestos antagonistas selectivos de los receptores iglur5, uso de dichos compuestos antagonistas selectivos en la manufactura de medicamentos para el tratamiento de migranas y dichos compuestos antagonistas
BRPI0311189B8 (pt) composições farmacêuticas contendo polimorfo a de flibanserin, bem como seu uso
NO20041059L (no) Kombinasjon av utvalgte opioder med muskarinantagonister for behandling av urininkontinens
PE20011223A1 (es) Composicion farmaceutica que comprende pemetrexed y un antioxidante como monotioglicerol, l-cisteina y acido tioglicolico
SV2008002856A (es) 2-amino-7, 8-dihidro-6h-pirido [4,3-d] pirimidina-5-onas
EA200300406A1 (ru) Фармацевтическая композиция дронедарона для парентерального введения
DE60117248D1 (de) Parenterale lösung enthaltend amiodaron

Legal Events

Date Code Title Description
FC Refusal